CDK1 and acute myeloid leukemia: HSN748-treated cells showed reduced expression of key survival genes, including AKT1, mTOR, S6K1, ELF4G1, STMN1, CDK1, and CDC23, correlating with greater overall survival of patients with AML compared with higher expression of these genes, correlating with the survival advantage of HSN748 treatment (Supplemental Figure 8).